Epigenomics

Benchamark reiterated its price target of $9 on Exact Sciences Corporation (NASDAQ: EXAS) in a research report published today. In the report, Benchmark states, "We believe EXAS shares already reflect some anticipation of favorable DDW presentations. Still, we anticipate some support from...